We work to enable HCM patients to live productive and fulfilling lives through clinical excellence, research, and education.
PODCAST
New on 11/13!A Breakthrough for Non-Obstructive HCM: Inside the ACACIA Trial Dr. Martin Maron, director of the HCM Center at Lahey Hospital & Medical Center and national principal investigator of the ACACIA-HCM trial, joins Dr. Florian Rader of the HCM Center at Cedars-Sinai to discuss the trial’s findings on aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (HCM). The conversation covers the long-standing treatment gap for non-obstructive patients who remain symptomatic on beta-blockers or calcium channel blockers, the phase 3 trial design, and its co-primary endpoints of health status (KCCQ) and exercise capacity (peak VO2). Dr. Maron explains the clinical significance of the results and reviews secondary outcomes, including improvements in NT-proBNP and diastolic function measures, alongside consistent benefits across pre-specified subgroups. Additionally, they discuss safety findings regarding ejection fraction reductions and heart failure events during dose titration, as well as potential real-world monitoring strategies if aficamten is approved for this indication.
Showcase your commitment to advancing HCM research and education are while engaging directly with the clinicians and researchers driving innovation in diagnosis, treatment, and patient outcomes.